BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, Castro-Fernández M, Dominguez-Muñoz E, Elizalde JI, Forné M, Gené E, Gomollón F, Lanas Á, Martín de Argila C, McNicholl AG, Mearin F, Molina-Infante J, Montoro M, Pajares JM, Pérez-Aisa A, Pérez-Trallero E, Sánchez-Delgado J. [III Spanish Consensus Conference on Helicobacter pylori infection]. Gastroenterol Hepatol 2013;36:340-74. [PMID: 23601856 DOI: 10.1016/j.gastrohep.2013.01.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP. Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterología y Hepatología 2013;36:39-50. [DOI: 10.1016/s0210-5705(13)70052-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
2 Campillo A, Amorena E, Ostiz M, Kutz M, Laiglesia M. Triple terapia 10 días con esomeprazol 40 mg/12 h vs. cuádruple concomitante sin bismuto como tratamiento de primera línea de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2016;39:584-9. [DOI: 10.1016/j.gastrohep.2016.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Morilla AM, Álvarez-Argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol 2019;42:476-85. [PMID: 31324461 DOI: 10.1016/j.gastrohep.2019.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Sebastián Domingo JJ. [Should H. pylori be eradicated before bariatric surgery?]. Gastroenterol Hepatol 2015;38:353-4. [PMID: 25709108 DOI: 10.1016/j.gastrohep.2014.12.007] [Reference Citation Analysis]
5 Cuadrado-Lavín A, Salcines-Caviedes JR, Diaz-Perez A, Carrascosa MF, Ochagavía M, Fernandez-Forcelledo JL, Cobo M, Fernández-Gil P, Ayestarán B, Sánchez B. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. J Antimicrob Chemother. 2015;70:2376-2381. [PMID: 25855760 DOI: 10.1093/jac/dkv089] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
6 Puig I, Baylina M, Sánchez-delgado J, López-gongora S, Suarez D, García-iglesias P, Muñoz N, Gisbert JP, Dacoll C, Cohen H, Calvet X. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016;71:2740-53. [DOI: 10.1093/jac/dkw220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
7 Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, Fischbach L, Bazzoli F, Gisbert JP. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;:CD009034. [PMID: 27351542 DOI: 10.1002/14651858.CD009034.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
8 Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
9 Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. Helicobacter 2020;25:e12693. [PMID: 32285569 DOI: 10.1111/hel.12693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 McNicholl AG, Garre A, Llorca L, Bujanda L, Molina-Infante J, Barenys M, Perez J, Guerrero-Torres MD, Tamayo E, Montes M, Prados-Manzano R, Sanchez-Garcia A, Ramas M, Valdez Blanco VB, Montoro M, Calvet X, Figuerola A, Lario S, Quilez E, Lanas A, Silva-Pomarino P, Perez-Aisa A, Donday MG, Belloc B, Montserrat-Torres A, Fernandez-Moreno N, Ramírez MJ, Alarcon T, Gisbert JP. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. Gastroenterol Hepatol 2020;43:117-25. [PMID: 31810793 DOI: 10.1016/j.gastrohep.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
12 Agudo-fernández S, González Blanco A. Análisis retrospectivo del uso de la cuádruple terapia con bismuto (Pylera®) en la práctica clínica real en España. Gastroenterología y Hepatología 2018;41:483-9. [DOI: 10.1016/j.gastrohep.2018.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
14 Cubiella J, Pérez Aisa Á, Cuatrecasas M, Díez Redondo P, Fernández Esparrach G, Marín-Gabriel JC, Moreira L, Núñez H, Pardo López ML, Rodríguez de Santiago E, Rosón P, Sanz Anquela JM, Calvet X; en representación de la Asociación Española de Gastroenterología, la Sociedad Española de Endoscopia Digestiva y la Sociedad Española de Anatomía Patológica. Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. Gastroenterol Hepatol 2021;44:67-86. [PMID: 33252332 DOI: 10.1016/j.gastrohep.2020.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
16 Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28): 9439-9450 [PMID: 25071338 DOI: 10.3748/wjg.v20.i28.9439] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
18 Pons C, Varas M, Gisbert JP, Barenys M, Pajuelo F, Fernández FJ. Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study). Gastroenterol Hepatol 2021;44:628-36. [PMID: 33248174 DOI: 10.1016/j.gastrohep.2020.10.016] [Reference Citation Analysis]
19 Gisbert JP, Barrio J, Modolell I, Molina-Infante J, Aisa AP, Castro-Fernández M, Rodrigo L, Cosme A, Gisbert JL, Fernández-Bermejo M, Marcos S, Marín AC, McNicholl AG. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Dig Dis Sci 2015;60:458-64. [PMID: 25236423 DOI: 10.1007/s10620-014-3365-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
20 Díez-Rodríguez R, Ballesteros-Pomar MD, Vivas-Alegre S, Barrientos-Castañeda A, González-de Francisco T, Olcoz-Goñi JL. [Upper endoscopy findings in obese morbid patients candidates for bariatric surgery]. Gastroenterol Hepatol 2015;38:426-30. [PMID: 25709107 DOI: 10.1016/j.gastrohep.2015.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
22 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
23 McNicholl AG, Forné M, Barrio J, De la Coba C, González B, Rivera R, Esteve M, Fernandez-Bañares F, Madrigal B, Gras-Miralles B, Perez-Aisa A, Viver-Pi-Sunyer JM, Bory F, Rosinach M, Loras C, Esteban C, Santolaria S, Gomollon F, Valle J, Gisbert JP; Helicobacter pylori Study Group of Asociación Española de Gastroenterología (AEG). Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol 2014;26:941-8. [PMID: 25014624 DOI: 10.1097/MEG.0000000000000132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
24 Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [DOI: 10.1111/hel.12586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Gisbert JP, Molina-Infante J, Amador J, Bermejo F, Bujanda L, Calvet X, Castro-Fernández M, Cuadrado-Lavín A, Elizalde JI, Gene E, Gomollón F, Lanas Á, Martín de Argila C, Mearin F, Montoro M, Pérez-Aisa Á, Pérez-Trallero E, McNicholl AG. IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2016;39:697-721. [PMID: 27342080 DOI: 10.1016/j.gastrohep.2016.05.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
26 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
27 García-Iglesias P, Botargues JM, Feu Caballé F, Villanueva Sánchez C, Calvet Calvo X, Brullet Benedi E, Cánovas Moreno G, Fort Martorell E, Gallach Montero M, Gené Tous E, Hidalgo Rosas JM, Lago Macía A, Nieto Rodríguez A, Papo Berger M, Planella de Rubinat M, Saló Rich J, Campo Fernández de Los Ríos R. Management of non variceal upper gastrointestinal bleeding: position statement of the Catalan Society of Gastroenterology. Gastroenterol Hepatol 2017;40:363-74. [PMID: 28109636 DOI: 10.1016/j.gastrohep.2016.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
28 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
29 Sebastián Domingo JJ. Review of the role of probiotics in gastrointestinal diseases in adults. Gastroenterol Hepatol 2017;40:417-29. [PMID: 28185664 DOI: 10.1016/j.gastrohep.2016.12.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]